A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia
- Ewing's Sarcoma
- Hodgkin Disease
- Late Effects
- Non Hodgkin Lymphoma
- Non-Metastatic Breast Carcinoma
- Osteosarcoma
- Soft Tissue Sarcoma, Adult, Stage IIC
- Testicular Germ Cell Tumor Mixed
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: All patients in the study will benefit from the PASCA post-treatment program with 4 visits : at 1 month (T1), 6 month (T2), 24 month (T3) and 60 month (T4) after the end of treatment.Masking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04671693
- Collaborators
- Malakoff-Humanis
- Fondation Apicil
- Fédération Leucémie Espoir
- Biogaran
- Le défi Anthony
- Novartis
- Roche Pharma AG
- Investigators
- Principal Investigator: Mauricette MICHALLET, PhD, MD Centre Leon Berard